APLS: Apellis Pharmaceuticals, Inc. Stock

by  •  • Comments Off on APLS: Apellis Pharmaceuticals, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 3,543.96
Enterprise Value ($M) 3,599.34
Book Value ($M) 237.12
Book Value / Share 1.91
Price / Book 14.95
NCAV ($M) 169.15
NCAV / Share 1.36
Price / NCAV 20.95

Profitability (mra)
Return on Invested Capital (ROIC) -0.35
Return on Assets (ROA) -0.32
Return on Equity (ROE) -1.29

Liquidity (mrq)
Quick Ratio 3.68
Current Ratio 4.36

Balance Sheet (mrq) ($M)
Current Assets 833.90
Assets 901.87
Liabilities 664.75
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
2 days ago 13G Morgan Stanley
11-22 13G/A Deep Track Capital, LP 4.82
11-14 13G/A T. Rowe Price Investment Management, Inc. 2.50 -52.64
11-08 13G/A Wellington Management Group Llp 12.81 -5.33
11-08 13G BlackRock, Inc. 5.10 0.00
02-14 13G/A EcoR1 Capital, LLC 9.40 77.14
02-14 13G/A Avoro Capital Advisors LLC 9.90 26.22
02-13 13G/A Vanguard Group Inc 8.06 3.73

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-05 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2024-08-01 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2024-05-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2024-02-29 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1)
2024-02-27 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-02-04 174,019 830,164 20.96
2025-02-03 98,016 582,428 16.83
2025-01-31 343,948 1,232,281 27.91
2025-01-30 219,109 768,453 28.51

(click for more detail)

Similar Companies
AMRX – Amneal Pharmaceuticals, Inc. ANAB – AnaptysBio, Inc.
ANNX – Annexon, Inc. ARQT – Arcutis Biotherapeutics, Inc.
ARVN – Arvinas, Inc.


Financial data and stock pages provided by
Fintel.io